Haldol Stungulyf, lausn 5 mg/ml Iceland - Icelandic - LYFJASTOFNUN (Icelandic Medicines Agency)

haldol stungulyf, lausn 5 mg/ml

essential pharma limited - haloperidolum inn - stungulyf, lausn - 5 mg/ml

Sporanox Hart hylki 100 mg Iceland - Icelandic - LYFJASTOFNUN (Icelandic Medicines Agency)

sporanox hart hylki 100 mg

janssen-cilag ab - itraconazolum inn - hart hylki - 100 mg

Certican Tafla 0,75 mg Iceland - Icelandic - LYFJASTOFNUN (Icelandic Medicines Agency)

certican tafla 0,75 mg

novartis healthcare a/s - everolimusum inn - tafla - 0,75 mg

Certican Tafla 0,5 mg Iceland - Icelandic - LYFJASTOFNUN (Icelandic Medicines Agency)

certican tafla 0,5 mg

novartis healthcare a/s - everolimusum inn - tafla - 0,5 mg

Darunavir Medical Valley Filmuhúðuð tafla 800 mg Iceland - Icelandic - LYFJASTOFNUN (Icelandic Medicines Agency)

darunavir medical valley filmuhúðuð tafla 800 mg

medical valley invest ab - darunavir propylene glycolate - filmuhúðuð tafla - 800 mg

Certican Tafla 0,25 mg Iceland - Icelandic - LYFJASTOFNUN (Icelandic Medicines Agency)

certican tafla 0,25 mg

novartis healthcare a/s - everolimusum inn - tafla - 0,25 mg

Sotalol Viatris (Sotalol Mylan) Tafla 40 mg Iceland - Icelandic - LYFJASTOFNUN (Icelandic Medicines Agency)

sotalol viatris (sotalol mylan) tafla 40 mg

viatris limited - sotalolum hýdróklóríð - tafla - 40 mg

Sotalol Viatris (Sotalol Mylan) Tafla 80 mg Iceland - Icelandic - LYFJASTOFNUN (Icelandic Medicines Agency)

sotalol viatris (sotalol mylan) tafla 80 mg

viatris limited - sotalolum hýdróklóríð - tafla - 80 mg

Orserdu European Union - Icelandic - EMA (European Medicines Agency)

orserdu

stemline therapeutics b.v. - elacestrant - brjóstakrabbamein - innkirtla meðferð - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.

Biktarvy European Union - Icelandic - EMA (European Medicines Agency)

biktarvy

gilead sciences ireland uc - bictegravir, meðferð með eviplera nýrnastarfsemi alafenamide, fúmarat - hiv sýkingar - veirueyðandi lyf til almennrar notkunar - biktarvy is indicated for the treatment of human immunodeficiency virus 1 (hiv 1) infection in adults and paediatric patients at least 2 years of age and weighing at least 14 kg i without present or past evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir. (sjá kafla 5.